Drug Profile
Dronabinol/cannabidiol - GW Pharmaceuticals
Alternative Names: GWP-42002/GWP-42003; GWP-42002:GWP-42003; GWP-42003/GWP-42002; GWP-42003:GWP-42002Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator GW Pharmaceuticals
- Class Anti-ischaemics; Antineoplastics; Antipsychotics; Cannabinoids
- Mechanism of Action Cannabinoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glioblastoma; Schizophrenia
- No development reported Cerebral ischaemia
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Cerebral-ischaemia(In neonates) in United Kingdom
- 05 May 2021 GW Pharmaceuticals has been acquired by Jazz Pharmaceuticals plc
- 26 Aug 2019 Phase-I clinical trials in Cerebral ischaemia (In neonates) in United Kingdom (unspecified route) (GW Pharma pipeline august 2019)